Osteosarcoma
Osteosarcoma Market

Osteosarcoma (osteogenic sarcoma) is the most common type of bone cancer, which usually develops in the bone's osteoblast cells. It mostly occurs in the long bones around the knee. Other sites are the upper leg, thighbone, lower leg, upper arm bone, or bone in the body, covering those in the pelvis, shoulder, and skull. It may spread to nearby tissues, like tendons or muscles, and may also metastasize via the bloodstream to other organs or bones in the body.


Osteosarcoma Epidemiological Segmentation 

The Epidemiological Segmentation of Osteosarcoma in 7MM from 2017 to 2030 is segmented as:- 

  • Total Incident Cases of Osteosarcoma
  • Gender-specific Incident Cases of Osteosarcoma
  • Age-specific Incident Cases of Osteosarcoma
  • Stage-specific Incident Cases of Osteosarcoma
  • Sub-types specific Incident Cases of Osteosarcoma
  • Site-specific Incident Cases of Osteosarcoma


Osteosarcoma Epidemiology 

  • The total incident population of Osteosarcoma in 7MM in 2017 was 2,181  
  • The incident cases of Osteosarcoma in the United States in 2017 was 1,141


Osteosarcoma Market

The therapeutic market of Osteosarcoma in 7MM in 2017 was USD 72.50 million  


Osteosarcoma Market Drivers

  • Robust pipeline
  • Increase in incidence
  • More Immunotherapies into clinical trials


Osteosarcoma Market Barriers

  • Drug Resistance
  • Lack of targeted therapies
  • No standard of care available for later lines
  • Complications associated with current therapies

 

Osteosarcoma Emerging Drugs

The emerging drugs of the Osteosarcoma market are 

  • Regorafenib
  • Cabozantinib S-malate
  • Bempegaldesleukin (NKTR-214)
  • Lenvatinib in Combination with Ifosfamide and Etoposide
  • Danyelza (Naxitamab/Hu3F8)
  • Pazopanib Hydrochloride (GW786034B/Votrient) and Topotecan Hydrochloride (Hycamtin)
  • Nab-rapamycin (ABI-009) with Nivolumab: Pepinemab (VX15/2503)
  • Nivolumab With or Without Ipilimumab
  • Inhaled Lipid-complexed Cisplatin (ILC)
  • Aliqopa (Copanlisib, BAY80-6946)
  • AU101
  • CAB-AXL-ADC (BA3011)
  • LN-145 (Autologous tumor-infiltrating lymphocytes)
  • Arfolitixorin (Modufolin)
  • Opdivo (nivolumab)
  • CB-103

And many others.  


Osteosarcoma Key Players

The key players in the Osteosarcoma market are

  • Bayer
  • Exelixis
  • Nektar Therapeutics
  • Eisai
  • Y-mAbs Therapeutics
  • GlaxoSmithKline/Novartis
  • Aadi Bioscience
  • Vaccinex, Inc
  • National Cancer Institute/Assaf-Harofeh Medical Center
  • Eleison Pharmaceuticals
  • Bayer
  • Aurora biopharma
  • BioAtla
  • Iovance Biotherapeutics
  • Isofol Medical AB
  • Bristol-Myers Squibb
  • Cellestia Biotech

And many others.